Clinical Trial Update: Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing pembrolizumab to standard treatment for recurrent or metastatic head and neck cancer has completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Head and Neck Squamous Cell Cancer | Phase 3 | Status: COMPLETED | Results posted: 2018-08-13